Abstract
Background: Concentration of serum free light chains has been promoted as an assay in the evaluation of monoclonal gammopathic manifestations. A high false-positive rate in patients without monoclonal gammopathic manifestations and a high false-negative rate in patients with those manifestations have been reported. The false-negative rate for lambda chain-associated lesions is higher than that for kappa chain-associated lesions. Objective: To assess the serum free light chains in light-chain myelomas. Methods: Concentrations of involved and uninvolved serum free light chains were retrospectively reviewed in patients with light-chain myelomas. Results: The highest recorded levels of involved light chains in kappachain myelomas and lambda-chain myelomas were comparable. The levels of uninvolved light chains were higher, although not statistically significantly, in lambda-chain lesions. Conclusions: The results of serum free light chains in light-chain myelomas support the clinical usefulness of the assay in monitoring patients with light chain myeloma.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 189-193 |
| Number of pages | 5 |
| Journal | Lab Medicine |
| Volume | 50 |
| Issue number | 2 |
| DOIs | |
| State | Published - Apr 8 2019 |
Keywords
- Light-chain myeloma
- Monoclonal gammopathy
- Multiple myeloma
- Serum free light chains
- Serum protein electrophoresis
- Urine protein electrophoresis
ASJC Scopus subject areas
- General Medicine